Join Growin Stock Community!

Briacell therapeutics corp. warrantBCTXZ.US Overview

US StockHealthcare
(No presentation for BCTXZ)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

BCTXZ AI Insights

BCTXZ Overall Performance

BCTXZ AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

BCTXZ Recent Performance

-4.53%

Briacell therapeutics corp. warrant

0.05%

Avg of Sector

-0.31%

S&P500

BCTXZ PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

BCTXZ Key Information

BCTXZ Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

BCTXZ Profile

BriaCell Therapeutics Corp., an immuno-oncology-focused biotechnology company, engages in developing immunotherapies for the management of cancer. Its lead drug candidate is Bria-IMT, a whole-cell cancer vaccine that is in Phase I/IIa clinical trials in combination with the immunotherapy development candidates retifanlimab. The company is also developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test that determines the patients' HLA types. It has a non-exclusive clinical trial collaboration with Incyte Corporation to evaluate the effects of combinations of novel clinical candidates; and a cooperative research and development agreement with the National Cancer Institute to conduct preclinical studies to develop and test Bria-OTS cellular immunotherapy as a treatment for cancer. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.

Price of BCTXZ

BCTXZ FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

BCTXZ Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-10.40
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-10.40
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is BCTXZ's latest earnings report released?

    The most recent financial report for Briacell therapeutics corp. warrant (BCTXZ) covers the period of 2025Q2 and was published on 2025/01/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating BCTXZ's short-term business performance and financial health. For the latest updates on BCTXZ's earnings releases, visit this page regularly.

  • How much cash does BCTXZ have?

    At the end of the period, Briacell therapeutics corp. warrant (BCTXZ) held Total Cash and Cash Equivalents of 12.46M, accounting for 0.73 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • What is the FCF of BCTXZ?

    Briacell therapeutics corp. warrant (BCTXZ)'s Free Cash Flow (FCF) for the period is -5.92M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 20.01% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.